Facts and figures
We are all in for better health
We at Teva are giving it our all for better health – better health for patients, communities and healthcare systems, better health for Teva employees globally, and better health for our planet by working sustainablyEnabling access to high quality medicines and treatment options
A new kind of pharmaceutical company
For over 120 years, Teva has been a different kind of biopharmaceutical company – one that operates across the full spectrum of innovation to continuously better health worldwide.
We do this by following the science to create the medicines needed today; driving the discovery and development of modern therapies; innovating throughout our established portfolio and promising pipeline; leveraging strategic partnerships to accelerate the development of therapies; streamlining the launches of generics and biosimilars through our legacy capabilities.
For healthcare professionals, patients, caregivers and families, we commit to push the boundaries to help deliver quality medicine wherever it is needed, discover life changing treatments and strive forward through scientific innovation.
Because when it comes to health, good is not enough for us.
THIS is the Teva legacy – to be stronger, bolder and simpler in the way we operate and relentless in our growth, by understanding what’s next – in science, for patients, people and society.
We are all in for better health
Moving forward together with science the treats, inspired by the people we serve.
We are Teva.
At Teva we believe that everyone should have access to quality medicine that helps manage disease, fights infection, or simply improves overall health.
From in-house innovation to strategic partnerships, we are persistently discovering, developing and delivering both generic and innovative medicines.
We are not defined by any one label.
Instead, our legacy in high-quality generics enables us to leverage our capabilities to bring forward complex generics and biosimilars at scale to create more value for patients and healthcare systems, and an improved health impact.
We maximise pivotal solutions that lead to better health for our patients and a stronger company for our people by delivering in the short-term to drive long-term stability.
Migraine
Chronic and episodic migraine
Oncology & Pain
Pain management and cancer therapies
We play an important role in delivering value to healthcare systems and economies around the world
The scale of production and accessible price of our products help to limit rising healthcare costs and improve patient health outcomes.
We also invest hundreds of millions of euros every year to enable our scientists to develop specialty and biopharmaceutical treatments that aim to improve patients’ health and increase access to medicines.
Delivering value to Ireland’s Healthcare System
In 2013 Ireland introduced compulsory generic medicines substitution and now, several years on, we’re seeing the real economic impact of that initiative.
Back in 2013 generic usage in the Irish medicines market was 11% but that figure rose to 58% in 2018.†
An estimated €1.6 billion in medicine savings was realised over the period 2013-2018, solely from generic substitution.‡
Teva as one of the largest suppliers of prescription medicines to the Health Service Executive¶ and a key partner to pharmacy in Ireland, has played an integral part in helping to drive these changes.
The chances are, someone you know is living a healthier life, because of our medicines - after all, we are one of the the largest suppliers of prescription medicines to Irish pharmacies¶
Investing in our operations in Ireland
Teva is a major employer in Ireland with hundreds of highly skilled colleagues working in our research and manufacturing facilities
We employ around 650 people with sites in Dublin and Waterford. We are committed to investing in Ireland and proud of our contribution to Irish GDP. ¥
Our commercial teams and support functions are based in Swords, near Dublin, they are complemented by field-based sales teams covering both primary and secondary care in Ireland.
The Waterford site is of major strategic importance within the Teva manufacturing network and is responsible for the manufacture and development of respiratory medicines and devices. It includes a research and development centre dedicated to the next generation respiratory devices and smart technologies for the treatment of respiratory conditions like asthma and Chronic Obstructive Pulmonary Disease.
We’re proud to say that our Waterford site consistently achieves excellent inspection outcomes from multiple regulatory agencies around the world.
Leveraging our global size and strength
Teva is a global pharmaceutical leader with a strong legacy in generics, a category-defying portfolio, an appetite for innovation, a culture of innovation and a boundary-pushing approach to supporting better health outcomes. All of these bring considerable benefits to patients in Ireland.
We are continually expanding our range of medicines, devices, services and partnerships to better meet the needs of Irish patients and to offer increased choice to healthcare professionals.
We produce approximately 76 billion tablets and capsules a year through our 49 manufacturing facilities in 26 countries.*
We are all in for better health
And that means all across Ireland, people you probably know are living a healthier life because of our medicines.
References
* Teva Global Operations - Internal Data Sources - As at November 2024
** We estimate that 200 million patients across six continents take one of our products every day - Internal analyses conducted by Teva's Global Insights, Access & Technologies Department estimating number of Teva consumers.
† Medicines for Ireland https://www.medicinesforireland.ie/wp-content/uploads/2017/06/Medicines_for_Ireland-Generics@5.pdf Accessed April 2025
‡ Based on Medicines for Ireland company and IMS data https://www.medicinesforireland.ie/wp-content/uploads/2017/06/Medicines_for_Ireland-Generics@5.pdf Accessed April 2025
¶ Teva Ireland - Data On File
§ Teva Ireland - Data on file
¥ Teva Economic Impact Report - Matrix Global Advisors estimate of Teva’s Macroeconomic Impact in Ireland in 2023
Fast track your career
We can offer you the chance to make a real difference in people's lives and add value to your career